SEC filings and other documents

Q2 2026 revenue up 9% YoY, but higher costs led to a net loss; MIMEDX acquisition announced.

All proposals passed, including director elections, auditor ratification, and compensation approvals.

Record revenue and high margins reflect a focused, innovation-driven surgical solutions strategy.

Q1 2026 saw 19% revenue growth and net profitability, with strong outlook reaffirmed.

Focused on surgical wound care, the company projects strong growth and new product launches.

Record revenue, margin expansion, and strong 2026 growth outlook driven by surgical focus.

Q3 revenue up 22% with margin gains; THP discontinued to focus on core surgical growth.

Strong Q2 growth, expanded leadership, and a robust product pipeline position the company for future success.

Q2 2025 delivered strong revenue growth and profitability, with strategic review underway for THP.

Q1 2025 delivered robust revenue growth, margin gains, and key product and platform launches.

Revenue up 33% to $86.7M, with strong segment growth and strategic investments in 2024.

Record Q3 revenue and strong growth reflect expanding adoption of advanced wound care platforms.

Record Q3 revenue and EBITDA growth, with ongoing investment in THP and new product initiatives.